Identification of a new pyruvate kinase M2 isoform (PKM2) activator for the treatment of non-small-cell lung cancer (NSCLC).

Abstract

Lung cancer is the number one cancer in terms of both mortality and incidence. Cancer cells differ from normal cells in that they can reprogram their metabolism to support a rapid proliferation rate and alter oxidative phosphorylation processes toward lactic acid fermentation, even under aerobic conditions. Therefore, we aimed to identify new compounds that might act as pyruvate kinase M2 isoform (PKM2) activators and to investigate their anti-cancer efficacy in non-small-cell lung cancer (NSCLC) cells. The molecular docking method was applied to screen PKM2 activators from our virtual natural products library. Then, compounds with promising docking scores were examined for cytotoxic effects in a panel of NSCLC cells using the MTT assay. Functional effects and therapeutic mechanisms were investigated by in vitro enzyme assays, western blotting (WB), and flow cytometry. Molecular docking showed that 0089-0022 acts as a potential PKM2 activator by binding to the kinase pocket. An in vitro enzyme activity assay showed that 0089-0022 is a direct PKM2 activator and that it effectively induces apoptosis in A549 and H1975 cells through inhibition of AKT phosphorylation. Our results suggest that 0089-0022 activates PKM2 and thus is a promising anti-cancer therapeutic candidate in NSCLC.

• Authors: Run-Ze Li, Xing-Xing Fan, Dan-Feng Shi, Guo-Yuan Zhu, Yu-Wei Wang, Lian-Xiang Luo, Hu-Dan Pan, Xiao-Jun Yao, Elaine Lai-Han Leung, Liang Liu
• Journal: Chemical biology & drug design (Chem Biol Drug Des) Vol. 92 Issue 5 Pg. 1851-1858 (11 2018) ISSN: 1747-0285 [Electronic] England
• PMID: 29931766 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © 2018 John Wiley & Sons A/S.

Chemical References

• Antineoplastic Agents
• Isoenzymes
• Sulfonamides
• Pyruvate Kinase

Topics

• Antineoplastic Agents (chemistry, metabolism, pharmacology, therapeutic use)
• Apoptosis (drug effects)
• Binding Sites
• Carcinoma, Non-Small-Cell Lung (drug therapy)
• Cell Line, Tumor
• Humans
• Isoenzymes (chemistry, metabolism)
• Lung Neoplasms (drug therapy)
• Molecular Docking Simulation
• Protein Structure, Tertiary
• Pyruvate Kinase (chemistry, metabolism)
• Sulfonamides (chemistry, metabolism, pharmacology, therapeutic use)